Pramodini Medicare IPO GMP Today, Price & Details
Pramodini Medicare IPO GMP Today, Price Band, Subscription Status, Allotment & Listing Details
About Pramodini Medicare
Pramodini Medicare is stepping into the public market via an SME IPO on the NSE, aiming to raise capital for its growth initiatives. The company operates within the healthcare sector, a space that continues to see robust demand and innovation in India. This IPO presents an opportunity for investors to participate in the expansion of a player in this vital industry.
Financially, Pramodini Medicare has demonstrated a positive trajectory, reporting revenue of ₹63.38 Cr and a Profit After Tax (PAT) of ₹17.38 Cr. This translates to an Earnings Per Share (EPS) of ₹7.88. The IPO itself is structured with a total issue size of ₹69 Cr, comprising a substantial fresh issue of ₹63.14 Cr and a smaller Offer for Sale (OFS) component of ₹5.9 Cr. This means a significant portion of the funds raised will directly flow into the company's operations and expansion plans.
In terms of competitive positioning, the company's performance suggests it's carving out a niche for itself within the healthcare landscape. The fresh capital infusion is earmarked for key business objectives, which will be crucial for enhancing its market presence and operational capabilities. Investors will be keen to see how this strategic deployment of funds translates into future growth and profitability.
Pramodini Medicare IPO — Investment Analysis
Pramodini Medicare's IPO is priced within a band of ₹110 to ₹118 per share. With an Earnings Per Share (EPS) of ₹7.88, the Price-to-Earnings (P/E) ratio at the upper end of the price band (₹118) works out to approximately 14.97x. This valuation needs to be viewed in the context of the SME sector and the company's specific growth prospects. While not excessively high, it's essential to compare this P/E with industry peers and the company's projected future earnings. The face value of ₹10 per share means the premium being sought is substantial, and investors will be betting on future performance to justify this pricing.
Looking at the financial health, the company has reported commendable figures. Revenue stands at ₹63.38 Cr, and PAT is ₹17.38 Cr, indicating a healthy profit margin. While specific EBITDA figures and return ratios like Return on Net Worth (RONW) and Return on Capital Employed (ROCE) aren't detailed here, the PAT to revenue ratio suggests strong operational efficiency. A PAT of ₹17.38 Cr on revenue of ₹63.38 Cr is an impressive margin, which is a positive sign for potential investors. The trajectory of these figures over the last few years would provide a clearer picture of consistent growth and financial stability.
The growth outlook for Pramodini Medicare appears promising, especially given the capital it intends to raise through the fresh issue. However, there are inherent risks to consider. The SME segment itself carries higher volatility compared to mainboard listings. Furthermore, the OFS component, though small at ₹5.9 Cr, means some existing shareholders are cashing out, which could be interpreted in various ways. Sector-specific risks within healthcare and the general economic climate also play a role. The ability of the company to execute its expansion plans effectively will be key to mitigating these risks and achieving its growth targets.
Subscription levels for SME IPOs often provide a strong indication of market sentiment. High subscription from Qualified Institutional Buyers (QIBs) and High Net-worth Individuals (HNIs) typically signals strong institutional confidence, while robust retail participation reflects broad investor interest. If the IPO sees significant oversubscription, it can lead to strong listing gains, a common aspiration for many retail investors in the SME space. Conversely, subdued subscription might suggest caution. It's crucial to monitor these subscription figures closely as they unfold, as they often precede market movements. Investors should consult a SEBI-registered financial advisor before making investment decisions.
Disclaimer: This analysis is auto-generated from publicly available financial data and should not be considered investment advice. Always consult a SEBI-registered financial advisor before making investment decisions.
Pramodini Medicare IPO — Pros & Cons
Strengths
- The company has reported a strong Profit After Tax (PAT) of ₹17.38 Cr on a revenue of ₹63.38 Cr, showcasing impressive profitability. This healthy margin suggests efficient operations and pricing power, which is a significant positive for investors looking for financially sound businesses.
- A substantial portion of the IPO, ₹63.14 Cr out of ₹69 Cr, is a fresh issue. This means the capital raised will be directly injected into the company, fueling its growth plans and operational expansion, which can lead to future value creation for shareholders.
- The Earnings Per Share (EPS) stands at a healthy ₹7.88. This indicates a strong earning capacity per share, which is a fundamental metric that investors often look for when evaluating the profitability of a company.
- The P/E ratio of approximately 14.97x (at the upper price band of ₹118) is within a reasonable range for an SME IPO, especially considering the company's reported profitability. This suggests the valuation might not be overly stretched, offering potential for upside.
- The company operates in the healthcare sector, a resilient and growing industry in India with sustained demand. This sector-specific advantage provides a stable foundation for the company's business and future growth prospects.
Risks
- The IPO is for an SME segment company, which inherently carries higher investment risks and volatility compared to mainboard listed companies. This means investors need to be prepared for potentially larger price swings and liquidity challenges.
- While the fresh issue is significant, there is an Offer for Sale (OFS) component of ₹5.9 Cr. This indicates that some existing shareholders are divesting their stake, which could raise questions about their confidence in the company's immediate future prospects.
- Specific details on crucial financial metrics like EBITDA, RONW, and ROCE are not provided in the data, making a comprehensive assessment of financial health and efficiency more challenging. Investors will need to rely on the provided PAT and revenue figures for now.
- The lot size of 1200 shares requires a minimum investment of ₹141,600 (at the upper price band of ₹118). This is a substantial amount, potentially limiting participation for smaller retail investors and requiring a significant commitment.
- As an SME IPO, liquidity in the stock might be lower post-listing compared to larger companies. This could make it more difficult for investors to enter or exit their positions quickly without impacting the stock price.
Pramodini Medicare IPO Details
| Company Name | Pramodini Medicare |
|---|---|
| IPO Type | SME |
| Exchange | NSE |
| Price Band | ₹110 - ₹118 |
| Face Value | ₹10 per share |
| Lot Size | 1200 shares |
| Min Investment | ₹141,600 |
| Total Issue Size | ₹69.00 Cr |
|---|---|
| Fresh Issue | ₹63.14 Cr |
| Offer for Sale | ₹5.90 Cr |
| Registrar | Purva Sharegistry (India) Pvt.Ltd. |
| Lead Manager | Smart Horizon Capital Advisors Pvt.Ltd. |
| IPO Status | Listed |
Pramodini Medicare IPO Dates
Pramodini Medicare IPO Subscription Status
Pramodini Medicare IPO Listing Performance
Pramodini Medicare IPO listed on NSE on 19 Aug 2026 at ₹120, a premium of 1.7% over the issue price of ₹118. Investors who received allotment made a profit of ₹2,400 per lot (1200 shares) on listing day.
Pramodini Medicare IPO — Key Highlights
- Pramodini Medicare has reported a robust PAT of ₹17.38 Cr, indicating strong profitability relative to its revenue of ₹63.38 Cr.
- The IPO features a substantial fresh issue of ₹63.14 Cr, signaling direct capital infusion for the company's growth.
- The P/E ratio stands at approximately 14.97x at the upper price band of ₹118, which appears reasonable for an SME.
- The company has an Earnings Per Share (EPS) of ₹7.88, reflecting its earning capacity.
- The total issue size is ₹69 Cr, with a significant portion dedicated to the company's expansion.
- The lot size is 1200 shares, requiring a minimum investment of ₹141,600 at the upper price band.
Pramodini Medicare Financial Performance
| Revenue | ₹63.38 Cr |
|---|---|
| PAT | ₹17.38 Cr |
| EPS | ₹7.88 |
Pramodini Medicare IPO Valuations & Key Metrics
Valuation Ratios
| EPS | ₹7.88 |
|---|---|
| P/E Ratio | 14.97x |
| Debt/Equity | 0.000 |
Return Metrics
Pramodini Medicare IPO Reservation / Allocation
Pramodini Medicare IPO Lead Manager & Registrar
Book Running Lead Manager
Smart Horizon Capital Advisors Pvt.Ltd.
IPO Registrar
Purva Sharegistry (India) Pvt.Ltd.
Pramodini Medicare IPO — Frequently Asked Questions
What is Pramodini Medicare IPO GMP today?
As of today, the Grey Market Premium (GMP) for Pramodini Medicare IPO is not available at this time. GMP values are updated daily based on grey market activity.
What is the price band and lot size of Pramodini Medicare IPO?
Pramodini Medicare IPO has a price band of ₹110 to ₹118 per equity share with a face value of ₹10. The minimum lot size is 1200 shares, requiring a minimum investment of ₹141,600 at the upper band.
What are the important dates for Pramodini Medicare IPO?
Pramodini Medicare IPO opens for subscription on 12 Aug 2026 and closes on 14 Aug 2026. Allotment is expected on 17 Aug 2026. The shares are expected to list on NSE on 19 Aug 2026.
What is the investor category allocation in Pramodini Medicare IPO?
The shares are reserved as follows — Qualified Institutional Buyers (QIB): 0.00%, Non-Institutional Investors (NII/HNI): 0.00%, and Retail Individual Investors: 36.68%.
How can I apply for Pramodini Medicare IPO?
You can apply for Pramodini Medicare IPO through your bank's net banking ASBA facility or via UPI-based application through any stockbroker platform. Ensure you have sufficient funds in your bank account as the amount will be blocked until allotment. The registrar for this IPO is Purva Sharegistry (India) Pvt.Ltd..
What is the subscription status of Pramodini Medicare IPO?
Pramodini Medicare IPO has been subscribed 3.66 times overall. Retail category: 0.00x, NII/HNI: 0.00x, QIB: 3.66x.
What is Pramodini Medicare IPO price band and lot size?
The Pramodini Medicare IPO comes with a price band of ₹110 to ₹118 per share. The lot size is fixed at 1200 shares. This means a minimum investment of ₹141,600 is required to apply for one lot at the upper price band of ₹118.
The face value of each share is ₹10.
Is Pramodini Medicare IPO worth investing in?
Pramodini Medicare presents an interesting case with its healthy reported PAT of ₹17.38 Cr on revenue of ₹63.38 Cr, indicating strong margins. The P/E of around 14.97x at the upper band is also not unreasonable for an SME. The significant fresh issue of ₹63.14 Cr is a positive sign for growth.
However, it's crucial to remember the inherent risks associated with SME IPOs, including higher volatility and potential liquidity issues. The OFS component also warrants consideration. Investors should conduct thorough due diligence and assess their risk appetite. This is informational analysis based on available data, not investment advice. Investors should consult a SEBI-registered financial advisor before making investment decisions.
What is Pramodini Medicare IPO GMP today?
Grey Market Premium (GMP) for IPOs is an unofficial indicator of demand and is not provided by the company or exchanges. While it can give a sense of market sentiment, it's highly speculative and can change rapidly. Relying solely on GMP for investment decisions is not advisable, as it doesn't reflect the company's fundamentals.
Any GMP figures should be treated with caution and are not part of official analysis.
How to apply for Pramodini Medicare IPO?
You can apply for the Pramodini Medicare IPO through your demat account using either the UPI or ASBA (Application Supported by Blocked Amount) facility. Your broker will guide you through the process on their platform. Funds for your application will be blocked until the allotment is finalized, and if you don't get an allotment, the funds will be released.
The registrar for this IPO is Purva Sharegistry (India) Pvt.Ltd.